Skip to main content

Table 5 Results of this analysis

From: Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Endpoints OR with 95% CI P value I2 (%)
Any AE 1.00 [0.81–1.24] 1.00 0
Headache 0.88 [0.67–1.27] 0.49 0
Nasopharyngitis/URI 0.95 [0.71–1.27] 0.75 6
Back pain 0.81 [0.49–1.33] 0.40 0
Dizziness 0.63 [0.43–0.92] 0.02 0
Diarrhea 0.83 [0.48–1.44] 0.52 0
Nausea 0.52 [0.25–1.05] 0.07 0
Weight gain 2.29 [0.51–10.34] 0.28 80
Peripheral edema 1.21 [0.56–2.62] 0.63 76
  1. Nasopharyngitis and upper respiratory tract infection were combined together during the analysis
  2. Abbreviations: URI upper respiratory infection, AE adverse events, OR odds ratio, CI confidence interval